Bendamustine moves forward for multiple myeloma in Japan
This article was originally published in Scrip
SymBio Pharmaceuticals has begun a Phase II clinical trial in Japan with its lead product candidate, bendamustine, for the treatment of multiple myeloma (MM).
You may also be interested in...
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.